Project 4: Willis

$214,169P20FY2016GMNIH

University Of New England, Biddeford ME

Investigators

Linked publications & trials

Paper 39502898 Paper 38464172 Paper 38330029 Paper 37776236 Paper 37537886 Paper 37042635 Paper 36449506 Paper 35712882 Paper 35509138 Paper 35240196 Paper 34787642 Paper 34399634 Paper 34224496 Paper 34045975 Paper 34029686 Paper 33913543 Paper 33593853 Paper 33534613 Paper 33504822 Paper 33086288 Paper 33057056 Paper 33043804 Paper 32627098 Paper 32597855 Paper 32132628 Paper 31912192 Paper 31877728 Paper 31874253 Paper 31795144 Paper 31696775 Paper 31616247 Paper 31601633 Paper 31430262 Paper 31369671 Paper 31270817 Paper 31132919 Paper 31013343 Paper 30969886 Paper 30915105 Paper 30739223 Paper 30417077 Paper 30370434 Paper 30259786 Paper 29749116 Paper 29740450 Paper 29572653 Paper 29526406 Paper 29371114 Paper 29309879 Paper 29300279 Paper 28855331 Paper 28723417 Paper 28701542 Paper 28504116 Paper 28450396 Paper 28438966 Paper 28320059 Paper 27911395 Paper 27397078 Paper 26820587 Paper 26716358 Paper 26694132 Paper 26495837 Paper 26494422 Paper 26335909 Paper 26025059 Paper 26024120 Paper 25993121 Paper 25955964 Paper 25853667 Paper 25670002 Paper 25281324 Paper 24977415 Paper 24629894 Paper 24576160 Paper 24269252 Paper 23994439 Paper 23845748 Paper 23636717 Paper 23483698

Abstract

The blood-brain barrier (BBB) is a highly regulated dynamic interface that separates the peripheral circulating blood supply from the central nervous system. Many acute and chronic neurodegenerative diseases show regional degenerative changes and modified BBB integrity. Migraine is a common and potentially debilitating neurological disorder characterized by a paroxysmal unilateral throbbing pain and is often associated with aura, nausea, vomiting, and photophobia. Triptans (serotonin IB/ID receptor agonists) are often used migraine therapy and are thought to relieve headache pain, in part, by inhibiting the release of pronociceptive transmitters through actions on 5HT1B/1D receptors on trigeminal afferent neurons. However, frequent use of triptans over an extended period increased the frequency of migraines in migraineurs, a condition termed medication overuse headache (MOH). Since migraineurs are the most susceptible to develop MOH, some common neuronal mechanisms between migraine and MOH may be expected. The mechanisms that underlie medication overuse headache are not fully understood. Evidence suggests that changes in BBB integrity may play a key role in several clinical situations in which migraine headache is a major feature. We suggest that prolonged exposure to triptans or medication withdrawal results in BBB dysfunction, increasing the potential for the induction of headache. To test this hypothesis, we will use neurochemical, and pharmacological strategies in a rat model of triptan-induced latent sensitization to determine potential structural and functional changes in BBB integrity in two pain pathway brain regions. Medication withdrawal will be precipitated with 5-HT1B/1D antagonist (GRI27935). Behavioral cutaneous allyodyna responses will be assessed and correlated to changes in BBB integrity. Establishing the mechanisms that underlie the pathobiology of MOH will assist in the development of new therapeutic strategies for the treatment of migraine and MOH.

View original record on NIH RePORTER →